Monte Rosa Therapeutics, Inc. (GLUE): R&D Expense
$141.50M
Year ended 2025-12-31
$170.69M
Trailing 12 months to 2026-06-30
+18.5%
3-year compound annual growth
+42.6%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $141.50M | +16.4% | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | $121.56M | +9.2% | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | $111.27M | +30.8% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $85.06M | +48.8% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $57.16M | +138.1% | 2023-03-16, From 2021-01-01 |
| 2020-12-31 | $24.00M | n/a | 2022-03-29, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $141.50M | +16.4% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $37.45M | -75.3% |
| Agenus Inc (AGEN) | 2025-12-31 | $79.34M | -49.0% |
| ImmunityBio, Inc. (IBRX) | 2024-12-31 | $190.14M | -18.2% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $409.62M | +11.4% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $95.67M | -10.8% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $166.42M | -34.0% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $243.77M | -42.5% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $228.30M | +9.5% |
Compare GLUE, ATRA, AGEN, IBRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗